	MAIL			12	2-13-57	##C		
PAT. 8-7	JAN E				Attorney Docket No:	205.5 PATENT		
13	3/	IN THE UNITED S	TATES PATEN	IT AND TRAD	EMARK OFFICE			
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE								
	Serial No.:	08/653,034	Group No.:	1205	wedding t	01		
	Filed:	May 24, 1996	Examiner:	unassigned	weller by	,		
	For: Novel Compounds and Methods for Synthesis and Therapy							
					FEB 10	1997		
	Assistant Commissioner for Patents							
	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 CFR 1.97 (b))  CERTIFICATE OF MAILING  I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.							
	(check and complete apropriate item below);							
	_	37 CFR 1.8 (a)	or	Па	37 CFR 1.10			

37 CFR 1.8 (a)		37 CFR 1.10
x with sufficient postage as	<u>10</u>	as "Express Mail Post
first class mail		Office to Addressee" Mailing Label No.
		Robin Torres
Λ		(Type or print name of person mailing paper)
Date:		Redrin Jarra
7		(Signature of person mailing paper)
<b>y</b>		

# IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 35,071

Tel. No.: (415) 572-6569

SIGNATURE OF ATTORNEY

Mark L. Bosse

Type or print name of attorney

Gilead Sciences, Inc. 353 Lakeside Drive

P.O. Address

Foster City, CA 94404



Attorney Docket No.\_

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al

Serial No.:

08/653,034

Group No.: 1205

Filed:

May 24, 1996

Examiner:

unassigned

For:

Novel Compounds and Methods for Synthesis

and Therapy

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. x Preliminary Statements

2. x FORM PTO - 1449 (Modified)

X Copies of Listed Information Items Accompanying This Statement

#### CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

(Signature of person mailing paper)

### Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071

SIGNATURE OF ATT

Tel. No.: (415) 572-6569

Mark L. Bosse
Type or print name of attorney

Gilead Sciences, Inc. 353 Lakeside Drive

P.O. Address

Foster City, CA 94404